In conclusion, we demonstrated that three anti-HER2 IgE antibodies selected from screening of 1840 scFv and 30 full length IgE clones, mediated in vitro anti-tumor activity against breast cancer cells, in both rodent and human immune contexts. This evidence concerns the gene ERBB2 and neoplasm.